5.6.6. surgical treatment urgency urinary incontinence. 5.6.6.1. bladder wall injection botulinum toxin-a mechanism action: primary mechanism action bont-a inhibition neurotransmitter release cholinergic neurons . onabotulinumtoxina (onabota; botox®) 100 u licenced europe treat oab persistent refractory non-neurogenic uui adults . efficacy: rct oab-wet patients whose symptoms adequately managed anticholinergics receive either bladder wall injections onabota (100 u) saline reported 50% reduction uui episodes/day whilst number micturitions/day reduced two patients receiving onabota . total 22.9% patients onabota arm fully dry, vs. 6.5% saline arm. sr meta-analysis comparing efficacy onabota, mirabegron anticholinergics adults idiopathic oab reported patients received onabota (100u) achieved greater reduction uui episodes, surgery, micturition frequency highest odds achieving dryness well >50% reduction baseline uui episodes per day . randomised, placebo-controlled pilot study, assessing effect onabota treatment refractory oab symptoms prostatectomy reported significantly improved qol iciq scores improvements daily frequency patients receiving onabota compared placebo . retrospective trial assessed onabota efficacy 65 non-obstructed men refractory oab reported significant improvement udi-6 score (-4.2) iiq-7 (-6.0) scores, compared baseline . retrospective, single-centre cohort study onabota treatment oab 120 patients lead lower cisc rates male patients prior de-obstructive surgery surgery-naïve patients (28.6% cisc group without prior surgery, 7.5% turp subgroup, 4.2% radical prostatectomy subgroup) . phase iiib trial randomised solifenacin-naive patients (10% males) refractory oab onabota, solifenacin placebo, showed patients receiving onabota significantly greater changes uui episodes (-3.19) compared solifenacin (-2.6) placebo (-1.33) . network meta-analysis (male population range 9.8-40.2%) compared onabota mirabegron demonstrated onabota associated improved outcomes frequency episodes per day (-0.43,[-1.22-0.37]) uui episodes per day (-0.46, [-1.46-0.53]) . tolerability safety: urinary retention utis two common adverse events onabota injection. reported adverse events include haematuria, dysuria post-treatment pain . compared mirabegron, onabota associated higher risk uti treatment emergent adverse events . retrospective analysis compared use cisc onabota injection, among men previous prostatectomy vs. without prior surgery . 7.5% catheterisation rate turp, 4.2% rate radical prostatectomy 28.6% rate men without prior prostate surgery reported. practical considerations: bont-a injections recommended treatment option men refractory uui. despite lack universally accepted injection protocol, gender specific studies absence studies bpo patients, bont-a seems superior medical therapy. associated with, higher utis urinary retention risk coupled need repeated injections. dedicated series male population, focused treatment persistence, shown high discontinuation rate (68.8%) . patients treated oab onabota treatment undergone prior de-obstruction likely develop retention subsequent cisc. summary evidencelea single treatment session onabota (100 u) injected bladder wall effective placebo curing improving uui/oab symptoms qol.1bthere evidence repeated injections onabota reduced efficacy, discontinuation rates high.3there increased risk urinary retention uti onabota injections.2 recommendationsstrength ratingoffer bladder wall injections onabotulinumtoxina (100 u) patients overactive bladder/urgency urinary incontinence refractory medical therapy.weakwarn patients limited duration response, risk urinary tract infection possible prolonged need clean intermittent self-catheterisation (ensure willing able so).strong 5.6.6.2. sacral nerve stimulation (neuromodulation) mechanism action: sacral neuromodulation (snm) delivers low amplitude electrical impulses sacral nerve roots via electrode implanted adjacent third sacral nerve root connected attached pulse generator implanted buttock. works modulating neural activity thus stabilising bladder electrical activity unknown mechanism. two-stage process: first stage, tined lead electrode placed percutaneously near s3 (or found, near s4) root linked external stimulator assess response. symptoms reduced 50%, patients candidates second stage full implant. efficacy: several trials assess clinical effectiveness snm. rcts suffer limitation patients assessors cannot blinded treatment allocation since recruited subjects respond test phase randomisation. addition, percentage male population trials around 10%. meta-analysis compared effectiveness snm onabota reported significant difference successfully treated cases six-month follow-up (rr 0.93; 95% ci: 0.63-1.39) . tolerability safety: main complications snm pain implant site (13-42%), lead migration (4.0-21%), leg back pain (3.0-18%) wound infection (5.7-6.7%). surgical revision required 29-33% patients due device malfunction, battery device replacement lead migration . practical considerations: snm represents alternative onabota patients refractory oab, shown good success rates acceptable safety profile. summary evidencelesacral nerve neuromodulation effective failed conservative treatment oab/uui, sham controls used.2a recommendationstrength ratingoffer sacral neuromodulation patients urgency urinary incontinence refractory medical therapy willing undergo surgical treatment.weak 5.6.6.3. cystoplasty/urinary diversion mechanism action: augmentation cystoplasty involves interposition detubularised segment bowel bivalved bladder wall, aiming increase bladder capacity reduce oab related symptoms. urinary diversion remains reconstructive option patients intractable uui multiple pelvic procedures, radiotherapy pelvic pathology leading irreversible sphincteric incompetence fistula formation. efficacy: rcts comparing bladder augmentation treatments patients refractory oab/uui. large study three years follow-up augmentation cystoplasty resulted post-operative continence rate 93% idiopathic detrusor overactivity patients, 78% neurogenic overactivity 90% aus implanted, respectively . largest case series bladder augmentation idiopathic population included women . average follow 75.4 months 53% continent satisfied surgery, whereas 25% occasional leaks 18% continued disabling uui. small prospective mixed gender trial reported high patient satisfaction rates augmentation cystoplasty vs. onabota therapy . small study comparing ileal colonic conduits concluded differences relative risks uut infection uretero-intestinal stenosis . however, studies specifically examined techniques treatment intractable oab/uui . therefore, careful consideration operation undertaken depend thorough pre-operative counselling, access stoma/continence nurses well patient factors allow fully informed patient choice. tolerability safety: cystoplasty urinary diversion major urological operations. early post-operative complications include infection, bowel obstruction, bleeding, cardiorespiratory complications. long-term complications include metabolic disturbances (hyperchloraemic metabolic acidosis ileum used), change bowel habits, increased mucus production, stone formation, bladder perforation rarely bladder cancer . following augmentation cystoplasty diversion, majority patients depend self-catheterisation bladder emptying. patients urinary conduit depend lifelong urine bags. practical considerations: augmentation cystoplasty urinary diversion represent realistic treatment options men refractory oab. however, options involve major operation, non-negligible long-term complication rate lifelong reliance catheterisation urine bags. figure 6. evaluation management urinary incontinence non-neurogenic male luts dre = digital-rectal examination; ui = urinary incontinence; uti = urinary tract infection; pfmt = pelvic floor muscle training; ptns = posterior tibial nerve stimulation; bpo = benign prostatic obstruction. summary evidencelethere limited evidence effectiveness augmentation cystoplasty urinary diversion treatment idiopathic oab.3the need perform cisc following augmentation cystoplasty high.3augmentation cystoplasty urinary diversion associated high risks short- long-term complications.3there evidence comparing efficacy adverse effects augmentation cystoplasty urinary diversion.3 recommendationsstrength ratingoffer augmentation cystoplasty patients overactive bladder (oab)/urgency urinary incontinence (uui) failed treatment options able willing perform self-catheterisation.weakinform patients undergoing augmentation cystoplasty high risk complications; risk perform clean intermittent self-catheterisation need life-long surveillance.strongonly offer urinary diversion patients failed less invasive therapies treatment oab/uui, accept stoma.weak